A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

Limited therapeutic options exist for the treatment of patients with triple negative breast cancer (TNBC). Neoadjuvant chemotherapy is currently the standard of care treatment in the early stages of the disease, although reliable biomarkers of response have been scarcely described. In our study we e...

Full description

Bibliographic Details
Main Authors: Javier Pérez-Pena, Janos Tibor Fekete, Raquel Páez, Mariona Baliu-Piqué, José Ángel García-Saenz, Vanesa García-Barberán, Aránzazu Manzano, Pedro Pérez-Segura, Azucena Esparis-Ogando, Atanasio Pandiella, Balázs Gyorffy, Alberto Ocana
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
triple negative breast cancer
chemotherapy treated patients
transcriptomic signature
outcome
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02802/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.02802/full

Similar Items